<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3005245383
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Redunix 50 mg per 20 ml 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TREPROSTINIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous, Subcutaneous
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14111.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DR. REDDY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DR. REDDY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Redunix is</strong></p><p>The active ingredient of Redunix Solution For Infusion is treprostinil.</p><p>Treprostinil belongs to a group of medicines which work in a similar way to the naturally occurring prostacyclins. Prostacyclins are hormone-like substances which reduce blood pressure by relaxing blood vessels, causing them to widen, which allows the blood to flow more easily. Prostacyclins can also have an influence in preventing blood from clotting.</p><p><strong>What Redunix is used for</strong></p><p>Redunix is used to treat idiopathic or heritable pulmonary arterial hypertension (PAH) in patients with moderate severity of the symptoms. Pulmonary arterial hypertension is a condition where your blood pressure is too high in the blood vessels between the heart and the lungs, causing shortness of breath, dizziness, tiredness, fainting, palpitations or abnormal heartbeat, dry cough, chest pain and swollen ankles or legs.</p><p>Redunix is initially administered as a continuous subcutaneous (under the skin) infusion. Some patients may become unable to tolerate this because of local site pain and swelling. Your doctor will decide whether Redunix can be administered by continuous intravenous (directly into a vein) infusion instead. This will require the insertion of a central venous tube (catheter) that is usually located in your neck, chest or groin.</p><p><strong>How Redunix works</strong></p><p>Redunix lowers blood pressure within the pulmonary artery, by improving blood flow and reducing the amount of work for the heart.</p><p>Improved blood flow leads to an improved supply of oxygen to the body and reduced strain on the heart, causing it to function more effectively. Redunix improves the symptoms associated with PAH and the ability to exercise in patients who are limited in terms of activity.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Redunix</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (hypersensitive) to treprostinil or any of the other ingredients of this medicine listed in section 6</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been diagnosed with a disease called <strong>&ldquo;pulmonary veno-occlusive disease&rdquo;.</strong></p><p>This is a disease in which the blood vessels that carry blood through your lungs become swollen and clogged resulting in a higher pressure in the blood vessels between the heart and the lungs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe <strong>liver disease</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a <strong>heart problem</strong>, for example:</p><p>o&nbsp;&nbsp; a <strong>myocardial infarction</strong> (heart attack) within the last six months</p><p>o&nbsp;&nbsp; severe <strong>changes in heart rate</strong></p><p>o&nbsp;&nbsp; severe <strong>coronary heart disease or unstable angina</strong></p><p>o&nbsp;&nbsp; <strong>a heart defect</strong> has been diagnosed, such as a faulty heart valve that causes the heart to work poorly</p><p>o&nbsp;&nbsp; any disease of the heart which is not being treated or not under close medical observation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are at a specific high risk of bleeding</p><p>&ndash; for example, active stomach ulcers, injuries, or other bleeding conditions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a <strong>stroke within the last 3 months</strong>, or any other interruption of blood supply to the brain.</p><p><strong>Warnings and precautions</strong></p><p>Before you start taking Redunix, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from any <strong>liver disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from <strong>kidney disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been advised that you are <strong>medically obese</strong> (BMI greater than 30 kg/m<sup>2</sup>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>Human Immunodeficiency Virus (HIV) infection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>high blood pressure</strong> in your liver veins (portal hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a <strong>birth defect</strong> <strong>in your heart</strong> which affects the way your blood flows through it</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on a <strong>low sodium diet</strong>.</p><p>During your treatment with Redunix, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your blood pressure decreases (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you experience a rapid increase in breathing difficulties or persistent cough (this can be related to congestion in the lungs or asthma or other condition), <strong>consult your doctor immediately</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have excessive bleeding as Redunix may increase the risk, by preventing your blood from clotting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you develop a fever whilst receiving intravenous Redunix or the intravenous infusion site becomes red, swollen and / or painful to the touch, as this could be a sign of infection.</p><p><strong>Other medicines and Redunix</strong></p><p>Please tell your doctor if you are taking or have recently taken, might use any other medicines.</p><p>Please tell your doctor if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat <strong>high blood pressure</strong> (antihypertensive drugs or other vasodilators)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drugs used to increase the rate of <strong>urination</strong> (diuretics) including furosemide</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that stop <strong>blood clotting</strong> (anticoagulants) such as warfarin, heparin or nitric oxide based products</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any non-steroidal anti-inflammatory (<strong>NSAID</strong>) drugs (e.g. acetylsalicylic acid, ibuprofen).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that may increase or decrease the effect of Redunix (e.g. gemfibrozil, rifampicin, trimethoprim, deferasirox, phenytoin, carbamazepine, phenobarbital, St John&rsquo;s Wort) as your doctor may need to adjust your dose of Redunix.</p><p><strong>Pregnancy and breastfeeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Redunix is not recommended if you are pregnant, planning to become pregnant, or think that you might be pregnant, unless considered essential by your doctor. The safety of this medicine for use during pregnancy has not been established.</p><p>Redunix is not recommended for use in breastfeeding, unless considered essential by your doctor. You are advised to stop breastfeeding if Redunix is prescribed for you, because it is not known whether this medicine passes into breast milk.</p><p>Contraception is strongly recommended during Redunix treatment.</p><p><strong>Driving and using machines</strong></p><p>Redunix may induce low blood pressure with dizziness or fainting. In such a case do not drive or operate machinery and ask your doctor for advice.</p><p><strong>Redunix contains sodium</strong></p><p>This medicine contains up to 78.4 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 3.7 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor if you are not sure.</p><p>Redunix is administered as a continuous infusion, either:</p><p>&bull; subcutaneously (under the skin) via a small tube (cannula) which is located in your abdomen or thigh;</p><p>or,</p><p>&bull; intravenously via a tube (catheter) that is usually located in your neck, chest or groin.</p><p>For subcutaneous infusion the product should be administered undiluted.</p><p>For intravenous infusion the product should be diluted in accordance with the instructions of the prescriber and may only be diluted with sterile water for injection or 0.9% (w/v) sodium chloride solution.</p><p>In both cases, Redunix is pushed through the tubing by a portable pump.</p><p>Before you leave the hospital or clinic, the doctor will tell you how to prepare Redunix and at what rate the pump should deliver your Redunix. Information on how to use the pump correctly and what to do if it stops working should also be given to you. The information should also tell you who to contact in case of emergency.</p><p>Flushing of the infusion line whilst connected may cause accidental overdose.</p><p>Redunix is diluted only when administered intravenously:</p><p><strong>For intravenous infusion only</strong>: You must only dilute your Redunix solution with either Sterile Water for Injection or 0.9% Sodium Chloride solution (as provided by your doctor) if it is being administered as a continuous intravenous infusion.</p><p><u>Adult patients</u></p><p>Treprostinil is available as 2.5 mg/ml or 5 mg/ml solution for infusion. Your doctor will determine the infusion rate and the dose appropriate for your condition.</p><p><u>Overweight patients</u></p><p>If you are overweight (weigh 30% or more than your ideal body weight) your doctor will determine the initial and subsequent doses based on your ideal body weight. Please also refer to Section 2, &ldquo;Warnings and precautions&rdquo;.</p><p><u>Older people</u></p><p>Your doctor will determine the infusion rate and the dose appropriate for your condition.</p><p><u>Children and adolescents</u></p><p>Limited data are available for children and adolescents.</p><p><u>Dosage adjustment</u></p><p>The infusion rate can be reduced or increased on individual bases under <strong>medical supervision only.</strong></p><p>The aim of adjusting the infusion rate is to establish an effective maintenance rate which improves symptoms of PAH while minimizing any undesirable effects.</p><p>If your symptoms increase or if you need complete rest, or are confined to your bed or chair, or if any physical activity brings on discomfort and your symptoms occur at rest, do not increase your dose without medical advice.</p><p>Redunix may no longer be sufficient to treat your disease and another treatment may be required.</p><p><strong>How can blood stream infections during treatment with intravenous Redunix be prevented?</strong></p><p>As with any long-term intravenous treatment, there is a risk of getting blood stream infections. Your doctor will train you on how to avoid this.</p><p><strong>If you use more Redunix than you should</strong></p><p>If you accidentally overdose on Redunix, you may experience nausea, vomiting, diarrhoea, low blood pressure (dizziness, light-headedness or fainting), skin flushes and/or headaches.</p><p>If any of these effects become severe then you should contact your doctor or hospital specialist immediately. Your doctor may reduce or discontinue the infusion until your symptoms have disappeared. Redunix will then be reintroduced at a dose level recommended by your doctor.</p><p><strong>If you stop using Redunix</strong></p><p>Always use Redunix as directed by your doctor or hospital specialist. Do not stop using Redunix unless your doctor has advised you to.</p><p>Abrupt withdrawal or sudden reductions in the dose of Redunix may cause the pulmonary arterial hypertension to return with the potential for rapid and severe deterioration in your condition.</p><p>If you have any further questions on the use of this product, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels with flushing of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or tenderness around the infusion site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin discolouration or bruising around the infusion site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headaches</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaw pain</p><p><strong>Common side effects (may affect up to 1 in 10 people</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light-headedness or fainting due to low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching or redness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of feet, ankles, legs or fluid retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding episodes such as nose bleeds, coughing up blood, blood in the urine, bleeding from the gums, blood in the faeces</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain, muscle pain, pain in the legs and/or arms</p><p><strong>Other possible side effects (frequency cannot be estimated from the available data)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection at the infusion site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abscess at the infusion site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease of blood clotting cells (platelets) in the blood (thrombocytopenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding at the infusion site</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes with discolouration or raised bumps</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissue infection under the skin (cellulitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too much pumping of blood from the heart leading to shortness of breath, fatigue, swelling of the legs and abdomen due to fluid build-up, persistent cough.</p><p>Additional side effects associated with the intravenous route of administration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the vein (thrombophlebitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood stream bacterial infection (bacteraemia)* (refer to Section 3)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; septicaemia (severe blood bacterial infection)</p><p>* life-threatening or fatal cases of blood stream bacterial infection have been reported</p><p><strong>Reporting of side effects</strong></p><p><u>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</u></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not store above 30&deg;C.</p><p>Do not use this medicine after the expiry date that is stated on the carton and vial after &ldquo;EXP&rdquo;.</p><p>The expiry date refers to the last day of that month.</p><p>Do not use Treprostinil if you notice any damage to the vial, discolouration or other signs of deterioration.</p><p>A Treprostinil vial must be used or discarded within 30 days after first opening.</p><p>During continuous subcutaneous infusion, a single reservoir (syringe) of undiluted Treprostinil must be used within 72 hours.</p><p>During continuous intravenous infusion, a single reservoir (syringe) of diluted Treprostinil must be used within 24 hours.</p><p>Any remaining diluted solution should be discarded.</p><p>For instructions on use please refer to Section 3. &ldquo;How to use Redunix&rdquo;.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Redunix Solution contains</p><p>The active substance is <strong>Treprostinil</strong></p><p>The other ingredients in Redunix are Sodium Chloride USP, Metacresol USP, Sodium citrate dihydrate USP-NF, Sodium hydroxide USP-NF, Hydrochloric acid USP-NF(for pH adjustment), Nitrogen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Treprostinil Solution is a clear colourless to slightly yellow solution, available in a 20 ml clear glass vial sealed with a rubber stopper and a colour coded flip-off seal:
• Treprostinil, 2.5 mg/ml Solution For Infusion has a rubber blue cap.
• Treprostinil, 5 mg/ml Solution For Infusion has a rubber green cap.
Each carton contains one vial.
Not all Strengths may be Marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER: </strong></p><p>&nbsp;</p><p>Sudair Pharma Company (SPC)</p><p>King Fahad Road &ndash;Riyadh Gallery Mall, Gate A1, 3rd floor Sudair pharma office, Building&nbsp; 7639, Riyadh 12262, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p><strong>Manufacturer:</strong></p><p>Dr. Reddy&rsquo;s Laboratories Limited FTO-9,</p><p>Plot No. Q1 to Q5, Phase - III, SEZ,</p><p>Duvvada, Visakhapatnam,</p><p>Andhra Pradesh - 530 046, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 12/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو ريدونيكس</strong></p><p dir="RTL">المادة الفعالة في محلول ريدونيكس للتنقيط هي تريبروتسينيل.</p><p dir="RTL">ينتمي تريبروستينيل إلى مجموعة من الأدوية التي تعمل بطريقة مشابهة لمواد البروستاسيكلين الموجودة بشكل طبيعي فى الجسم. مواد البروستاسيكلين هي مواد شبيهة بالهرمونات تخفض ضغط الدم عن طريق إرخاء الأوعية الدموية، مما يؤدي إلى اتساعها، ويتيح للدم أن يتدفق بسهولة أكبر. يمكن لمواد البروستاسيكلين كذلك أن تحفز منع تجلط الدم.</p><p dir="RTL"><strong>دواعي استخدام ريدونيكس</strong></p><p dir="RTL">يُستخدم ريدونيكس لعلاج ارتفاع ضغط الدم الشرياني الرئوي (PAH) مجهول السبب أو الموروث في المرضى ذوي الأعراض معتدلة الشدة. ارتفاع ضغط الدم الشرياني الرئوي هو حالة يكون فيها ضغط دمك أعلى مما ينبغي في الأوعية الدموية بين القلب والرئتين، مما يسبب ضيق التنفس، والدوخة، والتعب، والإغماء، والخفقان أو اضطراب ضربات القلب، والسعال الجاف، وألم الصدر، وتورم الكاحلين أو الساقين.</p><p dir="RTL">يُعطى ريدونيكس مبدئيًا في شكل تنقيط مستمر تحت الجلد. قد لا يتحمل بعض المرضى ذلك بسبب الألم والتورم الموضعيين. سيقرر الطبيب إن كان يمكن إعطاء ريدونيكس عن طريق التنقيط الوريدي المستمر (في الوريد مباشرةً) بدلًا من ذلك. سيتطلب ذلك تركيب أنبوب مركزي وريدي (قسطرة) توضع عادةً في عنقك أو صدرك أو في المنطقة الأربية.</p><p dir="RTL"><strong>طريقة عمل ريدونيكس</strong></p><p dir="RTL">يخفض ريدونيكس ضغط الدم في الشريان الرئوي عن طريق تحسين تدفق الدم والحد من مجهود القلب.</p><p dir="RTL">يؤدي تحسن تدفق الدم إلى تحسين إمداد الدم بالأكسجين والحد من إجهاد القلب، مما يزيد فاعليته. يحسن ريدونيكس الأعراض المرتبطة بارتفاع ضغط الدم الشرياني الرئوي والقدرة على بذل المجهود في المرضى محدودي النشاط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ريدونيكس</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا <strong>بالحساسية</strong> (فرط الحساسية) تجاه تريبروستينيل أو أي من المكونات الأخرى بهذا الدواء (مذكورة ضمن القسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن تم تشخيصك بمرض يُسمى <strong>&quot;داء الانسداد الوريدي الرئوي&quot;.</strong></p><p dir="RTL">وهذا مرض تصير فيه الأوعية الدموية التي تحمل الدم عبر رئتيك متورمة ومسدودة مما يؤدي إلى ارتفاع الضغط&nbsp; في الأوعية الدموية بين القلب والرئتين</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إن كنت مصابًا <strong>بمرض كبدي</strong> شديد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا <strong>بمشكلة قلبية</strong>، مثل:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>احتشاء عضلة القلب</strong> (الأزمة القلبية) في آخر ستة أشهر</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تغيرات معدل ضربات القلب</strong> الشديدة</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مرض شرايين القلب التاجية أو الذبحة الصدرية غير المستقرة</strong> الشديدة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشخيص <strong>عيب بالقلب</strong>، مثل خلل بأحد صمامات القلب مما يسبب خللًا بدوره في أداء القلب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي مرض بالقلب لم يُعالج أو ليس قيد الملاحظة الطبية عن كثب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت معرضًا بدرجة عالية وعلى وجه الخصوص لخطر النزيف</p><p dir="RTL">ويشمل ذلك مثلًا قروح المعدة النشطة، أو الإصابات، أو غير ذلك من حالات النزيف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت قد أصبت من قبل <strong>بسكتة دماغية في آخر 3 أشهر</strong>، أو بأي انقطاع في الإمداد الدموي للدماغ.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">أبلغ الطبيب قبل أن تبدأ استخدام ريدونيكس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من أي <strong>مرض كبدي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تعاني من أي <strong>مرض كلوي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كان تم تشخيصك من قبل بأنك <strong>مصاب بالسمنة طبيًا</strong> (مؤشر كتلة الجسم أعلى من 30 كجم/متر<sup>2</sup>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا <strong>بعدوى فيروس نقص المناعة البشرية (</strong><strong>HIV</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا <strong>بضغط الدم المرتفع</strong> في أوردتك الكبدية (ارتفاع ضغط الدم البابي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا <strong>بعيب خِلقي في قلبك</strong> مما يؤثر على الكيفية التي يتدفق بها الدم فيه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تخضع <strong>لنظام غذائي قليل الصوديوم</strong>.</p><p dir="RTL">أبلغ طبيبك أثناء علاجك باستخدام ريدونيكس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا انخفض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بزيادة سريعة في صعوبة التنفس أو السعال المستمر (يمكن أن يكون لذلك صلة بالاحتقان في الرئتين أو الربو أو حالة أخرى)، <strong>فاستشر الطبيب فورًا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أصبت بنزيف مفرط حيث يمكن أن يؤدي ريدونيكس إلى زيادة هذا الخطر، عن طريق منع دمك من التجلط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن أصبت بالحمى أثناء تلقي ريدونيكس في الوريد، أو إن أصيب موضع التنقيط الوريدي بالاحمرار و/أو التورم و/أو الألم عند لمسه، فيمكن أن يكون ذلك بمثابة علامة على حدوث إلتهاب.</p><p dir="RTL"><strong>الأدوية الأخرى وريدونيكس</strong></p><p dir="RTL">يُرجى أن تبلغ الطبيب إن كنت تستخدم حاليًا، أو إن كنت قد استخدمت مؤخرًا، أو ربما تستخدم أي أدوية أخرى.</p><p dir="RTL">يُرجى أن تبلغ الطبيب إن كنت تتلقى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لعلاج <strong>ضغط الدم المرتفع</strong> (أدوية ارتفاع ضغط الدم أو غيرها من موسعات الأوعية الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير المستخدمة لزيادة معدل <strong>التبول</strong> (مدرات البول) بما في ذلك فيوروسيمايد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تمنع <strong>تجلط الدم</strong> (مضادات التجلط) مثل الوارفارين أو الهيبارين أو المنتجات القائمة على أكسيد النيتريك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي من عقاقير <strong>مضادات الالتهاب غير الستيرويدية (</strong><strong>NSAID</strong><strong>)</strong> (مثل حمض الأسيتيل ساليسيليك والإيبوبروفين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تزيد تأثير ريدونيكس أو تقلله (مثل جيمفيبروزيل وريفامبيسين وترايميثوبريم وديفيراسيروكس وفينيتوين وكاربامازيبين وفينوباربيتال وعشبة القديس يوحنا) حيث قد يحتاج طبيبك إلى ضبط جرعة ريدونيكس.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إن كنتِ حاملًا أو مُرضعة، أو إن كنتِ تفكرين في الحمل أو تخططين للإنجاب، فاستشيري الطبيب قبل أن تستخدمي هذا الدواء.</p><p dir="RTL">لا يوصى باستخدام ريدونيكس إن كنتِ حاملًا، أو تخططين للحمل، أو تشكين في أنك حامل، ما لم يرَ الطبيب ذلك ضروريًا. لم يثبت أمان استخدام هذا الدواء أثناء الحمل.</p><p dir="RTL">يوصى بعدم استخدام ريدونيكس أثناء الرضاعة الطبيعية، ما لم يرَ الطبيب ذلك ضروريًا. يستحسن أن توقفي الرضاعة الطبيعية إن وُصف لك ريدونيكس، لأنه ليس من المعروف إن كان هذا الدواء يمر في حليب الثدي أم لا.</p><p dir="RTL">يوصى بشدة باستخدام وسائل لمنع الحمل أثناء العلاج باستخدام ريدونيكس.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يحفز ريدونيكس انخفاض ضغط الدم مع الدوخة أو الإغماء. وفي مثل تلك الحالة، لا تقم بالقيادة أو تشغيل الآلات واستشر الطبيب.</p><p dir="RTL"><strong>يحتوي ريدونيكس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على كمية تصل إلى 78.4 ملغم من الصوديوم (المكون الأساسي لملح الطهي/ملح الطعام) في كل قارورة. يكافئ ذلك 3.7% من الكمية القصوى الموصى بتناولها يوميًا من الصوديوم للشخص البالغ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على استخدام هذا الدواء مثلما أخبرك طبيبك. ينبغي أن تراجع طبيبك إذا لم تكن متأكدًا من أي معلومة.</p><p dir="RTL">يُعطى ريدونيكس في شكل تنقيط مستمر، إما:</p><p dir="RTL">&bull; تحت الجلد باستخدام أنبوب صغير (قسطرة صغيرة) توضع في البطن أو الفخذ،</p><p dir="RTL">أو</p><p dir="RTL">&bull; في الوريد باستخدام أنبوب (قسطرة) يوضع عادةً في عنقك أو صدرك أو في المنطقة الأربية.</p><p dir="RTL">في حالة التنقيط تحت الجلد، ينبغي إعطاء المنتج دون تخفيف.</p><p dir="RTL">في حالة التنقيط في الوريد، ينبغي تخفيف المنتج بما يتفق مع تعليمات القائم بوصف الدواء، ولا يمكن تخفيفه إلا باستخدام ماء معقم للحقن أو محلول كلوريد الصوديوم ذو تركيز 0.9% (وزن/حجم):</p><p dir="RTL">وفي كلتا الحالتين، يُدفع ريدونيكس عر الأنبوب باستخدام مضخة متنقلة.</p><p dir="RTL">قبل أن تغادر المستشفى أو العيادة، سيخبرك الطبيب بطريقة إعداد ريدونيكس وبالمعدل الذي ينبغي أن تعمل به المضخة على توصيل ريدونيكس لك. ينبغي أن تحصل على المعلومات المتعلقة بكيفية استخدام المضخة بطريقة صحيحة وما ينبغي القيام به في حالة توقفها عن العمل. ينبغي ايضا أن تحصل على المعلومات عن من ينبغي أن تتصل به في حالات الطوارئ.</p><p dir="RTL">قد يؤدي تنظيف أنبوب التنقيط أثناء توصيله إلى الحصول على جرعة مفرطة عن طريق الخطأ.</p><p dir="RTL">لا يُخفف ريدونيكس إلا في حالة الإعطاء في الوريد:</p><p dir="RTL"><strong>في حالة التنقيط الوريدي فقط</strong>: يجب ألا تخفف محلول ريدونيكس الخاص بك إلا باستخدام الماء المعقم للحقن أو محلول كلوريد الصوديوم ذو تركيز 0.9% (حسبما يحدد الطبيب).</p><p dir="RTL"><u>المرضى البالغون</u></p><p dir="RTL">يتوفر تريبروستينيل في شكل محلول تركيزه 2.5 ملغم/مل أو 5 ملغم/مل للتنقيط. سيحدد الطبيب معدل التنقيط والجرعة الملائمين لحالتك.</p><p dir="RTL"><u>المرضى زائدو الوزن</u></p><p dir="RTL">إن كان وزنك زائدًا (إن كان وزنك زائدًا بنسبة 30% أو أكثر عن وزن جسمك المثالي) فسيحدد الطبيب الجرعات المبدئية واللاحقة بناءً على الوزن المثالي لجسمك. يُرجى كذلك الرجوع للقسم 2، بعنوان &quot;التحذيرات والاحتياطات&quot;.</p><p dir="RTL"><u>المسنون</u></p><p dir="RTL">سيحدد الطبيب معدل التنقيط والجرعة الملائمين لحالتك.</p><p dir="RTL"><u>الأطفال واليافعون</u></p><p dir="RTL">لا تتوفر سوى بيانات محدودة بشأن الأطفال واليافعين.</p><p dir="RTL"><u>ضبط الجرعة</u></p><p dir="RTL">يمكن خفض معدل التنقيط أو زيادته على حسب حالة كل فرد تحت <strong>الإشراف الطبي فقط لا غير.</strong></p><p dir="RTL">يهدف ضبط معدل التنقيط إلى الوصول إلى معدل فعالية مستمر مما يحسن أعراض ارتفاع ضغط الدم الشرياني الرئوي مع الحد من أي آثار غير مرغوبة.</p><p dir="RTL">إن تزايدت أعراضك أو إن كنت في حاجة في الراحة التامة، أو إن كنت تلازم سريرك أو كرسيك، أو إن كان أي نشاط بدني يصيبك بالانزعاج وكانت أعراضك تحدث أثناء الراحة، فلا تُزد جرعتك دون نصيحة طبية.</p><p dir="RTL">قد لا يكون ريدونيكس كافيًا حينذاك لمعالجة مرضك وقد تكون في حاجة إلى علاج آخر.</p><p dir="RTL"><strong>كيف يمكن الوقاية من عدوى مجرى الدم أثناء العلاج باستخدام ريدونيكس وريديا؟</strong></p><p dir="RTL">كما هو الحال مع أي علاج وريدي طويل الأمد، توجد مخاطرة بالإصابة بعدوى مجرى الدم. سيدربك الطبيب على كيفية تجنب ذلك.</p><p dir="RTL"><strong>في حالة استعمال جرعة زائدة من ريدونيكس</strong></p><p dir="RTL">إن استخدمت جرعة مفرطة من ريدونيكس عن طريق الخطأ، فقد تصب بالغثيان و/أو القيء و/أو الإسهال و/أو انخفاض ضغط الدم (الدوخة أو الدوار أو الإغماء) و/أو احمرار الجلد و/أو الصداع.</p><p dir="RTL">إن صار أي من تلك التأثيرات شديدًا، فينبغي أن تتصل بالطبيب أو أخصائى المستشفى فورًا. قد يقلل طبيبك معدل التنقيط أو يوقفه حتى زوال الأعراض. سيجري استئناف استخدام ريدونيكس بعد ذلك بمستوى الجرعة الذي يوصي به الطبيب.</p><p dir="RTL"><strong>إن أوقفت استخدام ريدونيكس</strong></p><p dir="RTL">استخدم دومًا ريدونيكس حسب توجيهات الطبيب أو أخصائي المستشفى. لا توقف استخدام ريدونيكس ما لم ينصحك الطبيب بذلك.</p><p dir="RTL">قد يؤدي الإيقاف المفاجئ أو الخفض المفاجئ لجرعة ريدونيكس إلى التسبب في عودة ارتفاع ضغط الدم الشرياني الرئوي مع احتمالية التدهور السريع والشديد لحالتك.</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا المنتج، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدًا (قد تصيب أكثر من شخص واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الأوعية الدموية مع تورد (احمرار) الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ألم عند اللمس حول موضع التنقيط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون الجلد أو الكدمات حول موضع التنقيط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الفك</p><p dir="RTL"><strong>الآثار الجانبية الشائعة (قد تصيب ما يصل إلى شخص</strong><strong> </strong><strong>واحد من كل 10 أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوار أو الإغماء بسبب انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو احمرار الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم القدمين، الكاحلين، الساقين أو احتباس السوائل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات نزيف مثل نزيف الأنف، سعال مصحوب بخروج الدم ، وجود دم في البول، نزيف من اللثة، وجود دم في البراز</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مفاصل، ألم عضلات، ألم في الساقين و/أو الذراعين</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة (لا يمكن تقدير معدل التواتر من واقع البيانات المتاحة)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في موضع التنقيط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خراج في موضع التنقيط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص خلايا تجلط الدم (الصفائح الدموية) في الدم (قلة الصفيحات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في موضع التنقيط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العظام</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع تغير لون الجلد أو نتوءات بارزة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الأنسجة تحت الجلد (التهاب النسيج الخلوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضخ كمية أكثر مما ينبغي من الدم من القلب مما يؤدي إلى ضيق في التنفس، إرهاق، تورم الساقين والبطن بسبب تراكم السوائل، سعال مستمر.</p><p dir="RTL">آثار جانبية إضافية مرتبطة بالإعطاء عن طريق الوريد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد (التهاب الوريدي الخثاري)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بكتيرية بمجرى الدم (تجرثم الدم)* (يُرجى الرجوع للقسم 3)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنتان أو تعفن الدم (عدوى بكتيرية شديدة في الدم)</p><p dir="RTL">* وردت تقارير بشأن حالات مميتة أو قاتلة من العدوى البكتيرية بمجرى الدم</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ &lt;الطبيب&gt; &lt;أو&gt; &lt;مقدم الرعاية الصحية&gt; &lt;أو&gt; &lt;الصيدلي&gt;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول الأطفال ومرآهم.</p><p dir="RTL">لا يخزن في درجة حرارة أعلى من 30 مئوية.</p><p dir="RTL">لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية المبين على العبوة الكرتونية والقارورة بعد &quot;EXP&quot;.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم تريبروستينيل إن لاحظت تلفًا بالقارورة، أو تغيرًا باللون، أو أي علامات أخرى للتدهور.</p><p dir="RTL">يجب استخدام قارورة تريبروستينيل أو التخلص منها خلال 30 يومًا من فتحها لأول مرة.</p><p dir="RTL">أثناء التنقيط المستمر تحت الجلد، يجب استخدام مستودع واحد (محقنة واحدة) من تريبروستينيل غير المخفف خلال 72 ساعة.</p><p dir="RTL">أثناء التنقيط الوريدي المستمر، يجب استخدام مستودع واحد (محقنة واحدة) من تريبروستينيل غير المخفف خلال 24 ساعة.</p><p dir="RTL">ينبغي التخلص من أي بقايا للمحلول المخفف.</p><p dir="RTL">يُرجى الرجوع إلى القسم 3 بشأن تعليمات الاستخدام. &quot;طريقة استخدام ريدونيكس&quot;.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن طريق التخلص من الأدوية التي كففت عن استخدامها. ستساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محتويات محلول ريدونيكس</p><p dir="RTL">المادة الفعالة هي <strong>تريبروستينيل</strong>.</p><p dir="RTL">تتضمن المكونات الأخرى في ريدونيكس كلوريد الصوديوم حسب دستور الأدوية الأمريكي، وميتاكريسول حسب دستور الأدوية الأمريكي، وسترات الصوديوم ثنائية الهيدرات حسب دستور الأدوية الأمريكي-كتيب الوصفات الوطني، وهيدروكسيد الصوديوم حسب دستور الأدوية الأمريكي-كتيب الوصفات الوطني، وحمض الهيدروكسي كلوريد حسب دستور الأدوية الأمريكي-كتيب الوصفات الوطني (لضبط الرقم الهيدروجيني)، والنيتروجين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">محلول تريبروستينيل محلول صافٍ يتراوح بين انعدام اللون واللون الأصفر الفاتح، ويتوفر قارورة زجاجية سعتها 20 مل مغلقة بسدادة مطاطية وختم مشفر لونيًا وقابل للنزع:</p><p dir="RTL">&bull; محلول تريبروستينيل 2.5 ملغم/مل للتنقيط به غطاء سدادة أزرق.</p><p dir="RTL">&bull; محلول تريبروستينيل 5 ملغم/مل للتنقيط به غطاء سدادة أخضر.</p><p dir="RTL">تحتوي كل عبوة كرتونية على قارورة واحدة.</p><p dir="RTL">لا تُطرح كل التركيزات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق:</strong><strong> </strong></p><p>&nbsp;</p><p dir="RTL">شركة سدير للأدوية (SPC)</p><p dir="RTL">طريق الملك فهد - جاليري مول الرياض، البوابة A1، الطابق الثالث، مكتب شركة سدير للأدوية، المبنى 7639، الرياض 12262، المملكة العربية السعودية</p><p dir="RTL">الهاتف: 920001432-11-966+</p><p dir="RTL">الفاكس: 4668195-11-966+</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL"><strong>المصنّع:</strong></p><p dir="RTL">د. ريديز لابوراتوريز المحدودة إف تي أو-9،</p><p dir="RTL">القطعة رقم Q1 إلى Q5، المرحلة الثالثة، إس إي زد</p><p dir="RTL">دوفادا، فيزاخاباتنام</p><p dir="RTL">أندرا براديش &ndash; 046 530، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            جرت المراجعة الأخيرة لهذه النشرة في 12/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Redunix Solution for Infusion 2.5mg/mL
Redunix Solution for Infusion 5mg/mL 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The qualitative and quantitative composition of Treprostinil Injection 20mg/20mL (1mg/mL), 50mg/20mL (2.5mg/mL), 100mg/20mL (5mg/mL), and 200 mg/20mL (10 mg/mL) is given below.
Sodium Chloride USP, Metacresol USP, Sodium citrate dihydrate USP-NF, Sodium hydroxide USP-NF, Hydrochloric acid USP-NF(for pH adjustment), Nitrogen.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for Infusion (for subcutaneous or intravenous use)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of idiopathic or heritable pulmonary arterial hypertension (PAH) to improve exercise tolerance and symptoms of the disease in patients classified as New York Heart Association (NYHA) functional class III.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Redunix is administered by continuous subcutaneous or intravenous infusion. Due to the risks associated with chronic indwelling central venous catheters including serious blood stream infections, subcutaneous infusion (undiluted) is the preferred mode of administration and continuous intravenous infusion should be reserved for patients stabilised with Redunix subcutaneous infusion and who become intolerant of the subcutaneous route, and in whom these risks are considered acceptable.</p><p>The treatment should be initiated and monitored only by clinicians experienced in the treatment of pulmonary hypertension.</p><p>Redunix should be used undiluted if administered by continuous subcutaneous infusion; and should be diluted with sterile water injection or 0.9% (w/v) sodium chloride injection, if administered by continuous intravenous infusion. Please refer to the section 6.6.</p><p><strong><u>In adults</u></strong></p><p><u>Treatment initiation for patients new to prostacyclin therapy</u></p><p>Treatment should be initiated under close medical supervision in a medical setting able to provide intensive care.</p><p>The recommended initial infusion rate is 1.25 ng/kg/min. If this initial dose is poorly tolerated, the infusion rate should be reduced to 0.625 ng/kg/min.</p><p><u>Dose adjustments</u></p><p>The infusion rate should be increased under medical supervision in increments of 1.25 ng/kg/min per week for the first four weeks of treatment and then 2.5 ng/kg/min per week.</p><p>The dose should be adjusted on an individual basis and under medical supervision in order to achieve a maintenance dose at which symptoms improve and which is tolerated by the patient.</p><p>Efficacy in the main 12 week trials was only maintained if the dose was increased on average 3-4 times per month. The goal of chronic dosage adjustments is to establish a dose at which PAH symptoms are improved, whilst minimising the excessive pharmacological effects of Redunix.</p><p>Adverse effects, such as flushing, headache, hypotension, nausea, vomiting and diarrhoea, are generally dependent on the dose of Redunix administered. They may disappear as treatment continues, but should they persist or become intolerable to the patient, the infusion rate may be reduced to diminish their intensity.</p><p>During follow-up phases of clinical trials the mean doses reached after 12 months were 26 ng/kg/min, after 24 months were 36 ng/kg/min, and after 48 months were 42 ng/kg/min.</p><p>For patients with obesity (weighing &ge; 30% more than ideal body weight) initial dose and following dose increments should be based on ideal body weight.</p><p>Abrupt withdrawal or sudden marked reductions in the dose of Redunix may cause a rebound in pulmonary arterial hypertension. It is therefore recommended that interruption of Redunix therapy is avoided and that the infusion is re-started as soon as possible after an abrupt accidental dose reduction or interruption. The optimal strategy for reintroducing Redunix infusion needs to be determined on a case by case basis by medically qualified personnel. In most cases, after an interruption of a few hours, restarting of Redunix infusion can be done using the same dose rate; interruptions for longer periods may require the dose of Redunix to be re-titrated.</p><p><strong><u>In elderly</u></strong></p><p>Clinical studies of treprostinil did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. In a population pharmacokinetic (PK) analysis, plasma clearance of treprostinil was reduced by 20%. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p><p><strong><u>In children and adolescents</u></strong></p><p>There are few data in patients less than 18 years of age. Available clinical studies do not establish whether the efficacy and safety of the recommended posology scheme for adults can be extrapolated to children and adolescents.</p><p><strong><u>At risk populations</u></strong></p><p><u>Hepatic impairment</u></p><p>Plasma treprostinil exposure (area under the plasma concentration-time curve; AUC) increases by 260% to 510% in mild to moderate hepatic impairment, Child-Pugh classes A and B, respectively. Plasma clearance of treprostinil was reduced up to 80% in subjects presenting with mild to moderate hepatic impairment. Caution is therefore advised when treating patients with hepatic impairment because of the risk of an increase in systemic exposure which may reduce tolerability and lead to an increase in dose-dependent adverse effects.</p><p>The initial dose of treprostinil should be decreased to 0.625 ng/kg/min and incremental dose increases should be made cautiously.</p><p><u>Renal impairment</u></p><p>As no clinical studies have been carried out in patients with renal impairment, the treatment recommendations are not established for patients with renal impairment. As treprostinil and its metabolites are excreted mainly through the urinary route, caution is recommended when treating patients with renal impairment in order to prevent deleterious consequences related to the possible increase of systemic exposure.</p><p>&nbsp;</p><p><strong><u>Method of transition to intravenous epoprostenol treatment</u></strong></p><p>When transition to intravenous epoprostenol is required, the transition phase should be carried out under strict medical supervision. It may be useful for guidance purposes to note the following suggested treatment transition scheme. Redunix infusions should first be decreased slowly by 2.5 ng/kg/min. After at least 1 hour at the new Redunix dose, epoprostenol treatment can be initiated at a maximum dose of 2 ng/kg/min. The Redunix dose should then be decreased at subsequent intervals of at least 2 hours, and at the same time the epoprostenol dose is gradually increased after maintaining the initial dose for at least one hour.</p><p><strong><u>Mode of administration</u></strong></p><p><strong><u>Administration by continuous subcutaneous infusion</u></strong></p><p>Redunix is administered by continuous subcutaneous infusion via a subcutaneous catheter using an ambulatory infusion pump.</p><p>In order to avoid potential interruptions in drug delivery, the patient must have access to a backup infusion pump and subcutaneous infusion sets in the event that the administration equipment should suffer an accidental malfunction.</p><p>The ambulatory infusion pump used to administer undiluted Redunix subcutaneously, should be:</p><p>1) small and lightweight,</p><p>2) capable of adjusting infusion rates in increments of approximately 0.002 ml/h,</p><p>3) fitted with occlusion, low battery, programming error and motor malfunction alarms,</p><p>4) accurate to within +/- 6% of the programmed delivery rate</p><p>5) positive pressure driven (continuous or pulsated).</p><p>The reservoir must be made of polyvinyl chloride, polypropylene or glass.</p><p>Patients must be thoroughly trained in the use and programming of the pump, and the connection and care of the infusion set.</p><p>Flushing the infusion line whilst connected to the patient may lead to accidental overdose. Infusion rates &nabla; (ml/h) are calculated using the following formula:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nabla; (ml/h) = D (ng/kg/min) x W (kg) x [0.00006/ treprostinil concentration (mg/ml)]</p></td></tr></tbody></table><p>D = prescribed dose expressed in ng/kg/min</p><p>W = body weight of the patient expressed in kg</p><p>Treprostinil exists at strengths of 1, 2.5, 5 &amp; 10 mg/ml.</p><p>For subcutaneous infusion, Redunix is&nbsp;<strong>delivered without further dilution&nbsp;</strong>at a calculated Subcutaneous Infusion Rate (ml/h) based on a patients Dose (ng/kg/min), Weight (kg), and the Vial Strength (mg/ml) of Redunix being used. During use, a single reservoir (syringe) of undiluted Redunix can be administered up to 72 hours at 37&deg;C. The<u>&nbsp;Subcutaneous Infusion</u>&nbsp;rate is calculated using the following formula:</p><p>&nbsp;</p><p><img alt="" width="543" height="48" src="data:image/png;base64,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" /></p><p><em>*Conversion factor of 0.00006 = 60 min/hour x 0.000001 mg/ng</em></p><p>Example calculations for&nbsp;<strong><em>Subcutaneous Infusion&nbsp;</em></strong>are as follows:</p><p><strong><u>Example 1</u></strong><strong>:</strong></p><p>For a 65 kg person at a dose of 40 ng/kg/min using the 5 mg/ml Treprostinil Vial Strength, the infusion rate would be calculated as follows:</p><p><img alt="" width="554" height="61" src="data:image/png;base64,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" /></p><p>Tables 1 provides guidance for Treprostinil 2.5 mg/ml&nbsp;<strong>subcutaneous&nbsp;</strong>infusion delivery rates for patients of different body weights corresponding to doses of up to 42.5 ng/kg/min.</p><p><strong>Table 1 Infusion rate setting of subcutaneous pump (ml/h) for Redunix at a treprostinil strength of 2.5 mg/ml</strong></p><p><strong>Patient Weight (kg)</strong></p><p>&nbsp;</p><p><img alt="" width="585" height="501" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>Shaded areas indicate the highest infusion rate supported by one syringe changed every three days</strong></p><p>Table 2 provides guidance for Treprostinil 5 mg/ml&nbsp;<strong>subcutaneous&nbsp;</strong>infusion delivery rates for patients of different body weights corresponding to doses of up to 80 ng/kg/min.</p><p><strong>Table 2 Infusion rate setting of subcutaneous pump (ml/h) for Redunix at a treprostinil concentration of 5 mg/ml</strong></p><p>&nbsp;</p><p><img alt="" width="580" height="483" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><strong>Shaded areas indicate the highest infusion rate supported by one syringe changed every three days</strong></p><p><strong><u>Administration by continuous intravenous infusion</u></strong></p><p>Redunix is administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump. It may also be administered temporarily via a peripheral venous cannula, preferably placed in a large vein. Use of a peripheral infusion for more than a few hours may be associated with an increased risk of thrombophlebitis (see section 4.8).</p><p>In order to avoid potential interruptions in drug delivery, the patient must have access to a backup infusion pump and infusion sets in the event that the administration equipment malfunctions.</p><p>In general, the ambulatory infusion pump used to administer diluted Redunix intravenously should be:</p><p>1) small and lightweight</p><p>2) capable of adjusting infusion rates in increments of approximately 0.05 ml/hr. Typical flow rates would be between 0.4 ml and 2 ml per hour.</p><p>3) have occlusion / no delivery, low battery, programming error and motor malfunction alarms</p><p>4) have delivery accuracy of &plusmn;6% or better of the hourly dose</p><p>5) be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene or glass.</p><p><strong>Redunix should be diluted with either Sterile Water for Injection or 0.9% (w/v) Sodium Chloride Injection&nbsp;</strong>and is administered intravenously by continuous infusion, via a surgically placed indwelling central venous catheter, or temporarily via a peripheral venous cannula, using an infusion pump designed for intravenous drug delivery.</p><p>When using an appropriate infusion pump and reservoir, a predetermined intravenous infusion rate should first be selected to allow for a desired infusion period. The maximum duration of use of diluted Redunix should be no more than 24 hours (see section 6.3).</p><p>Typical intravenous infusion system reservoirs have volumes of 20, 50 or 100 ml. After determination of the required Intravenous Infusion Rate (ml/h) and the patient&#39;s Dose (ng/kg/min) and Weight (kg), the&nbsp;<u>Diluted Intravenous Treprostinil Concentration</u>&nbsp;(mg/ml) can be calculated using the following formula:</p><p><img alt="" width="540" height="77" src="data:image/png;base64,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" /></p><p>The amount of Treprostinil needed to make the required Diluted Intravenous Treprostinil Concentration for the given reservoir size can then be calculated using the following formula:</p><p><img alt="" width="554" height="72" src="data:image/png;base64,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" /></p><p>The calculated amount of Treprostinil is then added to the reservoir along with a sufficient volume of diluent (Sterile Water for Injection or 0.9% Sodium Chloride Injection) to achieve the desired total volume in the reservoir.</p><p>Example calculations for&nbsp;<strong><em>Intravenous Infusion&nbsp;</em></strong>are as follows:</p><p><strong><u>Example 2:</u></strong></p><p>For a 75 kg person at a dose of 30 ng/kg/min, with a predetermined intravenous infusion rate of 2 ml/h, and a reservoir of 100 ml, the Diluted Intravenous Treprostinil Solution Concentration would be calculated as follows:</p><p><img alt="" width="554" height="77" src="data:image/png;base64,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" /></p><p>The Amount of Treprostinil (using 2.5 mg/ml Vial Strength) needed for a total Diluted Treprostinil Concentration of 0.0675 mg/ml and a total volume of 100 ml would be calculated as follows:</p><p><img alt="" width="458" height="66" src="data:image/png;base64,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" /></p><p>The Diluted Intravenous Treprostinil Concentration for the person in Example 4 would thus be prepared by adding 2.7 ml of 2.5 mg/ml Treprostinil to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 100 ml in the reservoir. The pump flow rate for this example would be set at 2 ml/h.</p><p>Table 3 provides guidance for Treprostinil 2.5 mg for the volume (ml) of Treprostinil to be diluted in 20 ml, 50 ml or 100 ml reservoirs (0.4, 1, or 2 ml/h infusion rates, respectively) for patients of differing body weights corresponding to doses of up to 42.5 ng/kg/min.</p><p><strong>Table 3</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="17" style="vertical-align:top"><p><strong>Volume (ml) of Treprostinil 2.5 mg/ml to be diluted in cassettes or syringes</strong></p><p><strong>20 ml (0.4 ml/h infusion rate), 50 ml (1 ml/h infusion rate), 100 ml cassette (2 ml/h infusion rate)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Dose</strong></p><p><strong>(ng/ kg/ min)</strong></p></td><td colspan="16" style="vertical-align:top"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p><strong>45</strong></p></td><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p><strong>60</strong></p></td><td style="vertical-align:top"><p><strong>65</strong></p></td><td style="vertical-align:top"><p><strong>70</strong></p></td><td style="vertical-align:top"><p><strong>75</strong></p></td><td style="vertical-align:top"><p><strong>80</strong></p></td><td style="vertical-align:top"><p><strong>85</strong></p></td><td style="vertical-align:top"><p><strong>90</strong></p></td><td style="vertical-align:top"><p><strong>95</strong></p></td><td style="vertical-align:top"><p><strong>100</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>5</strong></p></td><td style="vertical-align:top"><p>0,150</p></td><td style="vertical-align:top"><p>0,180</p></td><td style="vertical-align:top"><p>0,210</p></td><td style="vertical-align:top"><p>0,240</p></td><td style="vertical-align:top"><p>0,270</p></td><td style="vertical-align:top"><p>0,300</p></td><td style="vertical-align:top"><p>0,330</p></td><td style="vertical-align:top"><p>0,360</p></td><td style="vertical-align:top"><p>0,390</p></td><td style="vertical-align:top"><p>0,420</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,480</p></td><td style="vertical-align:top"><p>0,510</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,570</p></td><td style="vertical-align:top"><p>0,60</p></td></tr><tr><td style="vertical-align:top"><p><strong>6,25</strong></p></td><td style="vertical-align:top"><p>0,188</p></td><td style="vertical-align:top"><p>0,225</p></td><td style="vertical-align:top"><p>0,263</p></td><td style="vertical-align:top"><p>0,300</p></td><td style="vertical-align:top"><p>0,338</p></td><td style="vertical-align:top"><p>0,375</p></td><td style="vertical-align:top"><p>0,413</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,488</p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,563</p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,638</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,7125</p></td><td style="vertical-align:top"><p>0,75</p></td></tr><tr><td style="vertical-align:top"><p><strong>7,5</strong></p></td><td style="vertical-align:top"><p>0,225</p></td><td style="vertical-align:top"><p>0,270</p></td><td style="vertical-align:top"><p>0,315</p></td><td style="vertical-align:top"><p>0,360</p></td><td style="vertical-align:top"><p>0,405</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,495</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,585</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,765</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,855</p></td><td style="vertical-align:top"><p>0,900</p></td></tr><tr><td style="vertical-align:top"><p><strong>8,75</strong></p></td><td style="vertical-align:top"><p>0.263</p></td><td style="vertical-align:top"><p>0,315</p></td><td style="vertical-align:top"><p>0,368</p></td><td style="vertical-align:top"><p>0,420</p></td><td style="vertical-align:top"><p>0,473</p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,578</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,683</p></td><td style="vertical-align:top"><p>0,735</p></td><td style="vertical-align:top"><p>0,788</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,893</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>0,998</p></td><td style="vertical-align:top"><p>1,050</p></td></tr><tr><td style="vertical-align:top"><p><strong>10</strong></p></td><td style="vertical-align:top"><p>0,300</p></td><td style="vertical-align:top"><p>0,360</p></td><td style="vertical-align:top"><p>0,420</p></td><td style="vertical-align:top"><p>0,480</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,660</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,780</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>0,960</p></td><td style="vertical-align:top"><p>1,020</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,140</p></td><td style="vertical-align:top"><p>1,200</p></td></tr><tr><td style="vertical-align:top"><p><strong>11,25</strong></p></td><td style="vertical-align:top"><p>0,334</p></td><td style="vertical-align:top"><p>0,405</p></td><td style="vertical-align:top"><p>0,473</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,608</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,743</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,878</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>1,013</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,148</p></td><td style="vertical-align:top"><p>1,215</p></td><td style="vertical-align:top"><p>1,283</p></td><td style="vertical-align:top"><p>1,350</p></td></tr><tr><td style="vertical-align:top"><p><strong>12,5</strong></p></td><td style="vertical-align:top"><p>0,375</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,750</p></td><td style="vertical-align:top"><p>0,825</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>0,975</p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,125</p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,275</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,425</p></td><td style="vertical-align:top"><p>1,500</p></td></tr><tr><td style="vertical-align:top"><p><strong>13,75</strong></p></td><td style="vertical-align:top"><p>0,413</p></td><td style="vertical-align:top"><p>0,495</p></td><td style="vertical-align:top"><p>0,578</p></td><td style="vertical-align:top"><p>0,660</p></td><td style="vertical-align:top"><p>0,743</p></td><td style="vertical-align:top"><p>0,825</p></td><td style="vertical-align:top"><p>0,908</p></td><td style="vertical-align:top"><p>0,990</p></td><td style="vertical-align:top"><p>1,073</p></td><td style="vertical-align:top"><p>1,155</p></td><td style="vertical-align:top"><p>1,238</p></td><td style="vertical-align:top"><p>1,320</p></td><td style="vertical-align:top"><p>1,403</p></td><td style="vertical-align:top"><p>1,485</p></td><td style="vertical-align:top"><p>1,568</p></td><td style="vertical-align:top"><p>1,650</p></td></tr><tr><td style="vertical-align:top"><p><strong>15</strong></p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>0,990</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,170</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,530</p></td><td style="vertical-align:top"><p>1,620</p></td><td style="vertical-align:top"><p>1,710</p></td><td style="vertical-align:top"><p>1,800</p></td></tr><tr><td style="vertical-align:top"><p><strong>16,25</strong></p></td><td style="vertical-align:top"><p>0,488</p></td><td style="vertical-align:top"><p>0,585</p></td><td style="vertical-align:top"><p>0,683</p></td><td style="vertical-align:top"><p>0,780</p></td><td style="vertical-align:top"><p>0,878</p></td><td style="vertical-align:top"><p>0,975</p></td><td style="vertical-align:top"><p>1,073</p></td><td style="vertical-align:top"><p>1,170</p></td><td style="vertical-align:top"><p>1,268</p></td><td style="vertical-align:top"><p>1,365</p></td><td style="vertical-align:top"><p>1,463</p></td><td style="vertical-align:top"><p>1,560</p></td><td style="vertical-align:top"><p>1,658</p></td><td style="vertical-align:top"><p>1,755</p></td><td style="vertical-align:top"><p>1,853</p></td><td style="vertical-align:top"><p>1,950</p></td></tr><tr><td style="vertical-align:top"><p><strong>17,5</strong></p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,735</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,155</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,365</p></td><td style="vertical-align:top"><p>1,470</p></td><td style="vertical-align:top"><p>1,575</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,785</p></td><td style="vertical-align:top"><p>1,890</p></td><td style="vertical-align:top"><p>1,995</p></td><td style="vertical-align:top"><p>2,100</p></td></tr><tr><td style="vertical-align:top"><p><strong>18,75</strong></p></td><td style="vertical-align:top"><p>0,563</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,788</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>1,013</p></td><td style="vertical-align:top"><p>1,125</p></td><td style="vertical-align:top"><p>1,238</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,463</p></td><td style="vertical-align:top"><p>1,575</p></td><td style="vertical-align:top"><p>1,688</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,913</p></td><td style="vertical-align:top"><p>2,025</p></td><td style="vertical-align:top"><p>2,138</p></td><td style="vertical-align:top"><p>2,250</p></td></tr><tr><td style="vertical-align:top"><p><strong>20</strong></p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,960</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,320</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,560</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,920</p></td><td style="vertical-align:top"><p>2,040</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,280</p></td><td style="vertical-align:top"><p>2,400</p></td></tr><tr><td style="vertical-align:top"><p><strong>21,25</strong></p></td><td style="vertical-align:top"><p>0,638</p></td><td style="vertical-align:top"><p>0,765</p></td><td style="vertical-align:top"><p>0,893</p></td><td style="vertical-align:top"><p>1,020</p></td><td style="vertical-align:top"><p>1,148</p></td><td style="vertical-align:top"><p>1,275</p></td><td style="vertical-align:top"><p>1,403</p></td><td style="vertical-align:top"><p>1,530</p></td><td style="vertical-align:top"><p>1,658</p></td><td style="vertical-align:top"><p>1,785</p></td><td style="vertical-align:top"><p>1,913</p></td><td style="vertical-align:top"><p>2,040</p></td><td style="vertical-align:top"><p>2,168</p></td><td style="vertical-align:top"><p>2,295</p></td><td style="vertical-align:top"><p>2,423</p></td><td style="vertical-align:top"><p>2,550</p></td></tr><tr><td style="vertical-align:top"><p><strong>22,5</strong></p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,215</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,485</p></td><td style="vertical-align:top"><p>1,620</p></td><td style="vertical-align:top"><p>1,755</p></td><td style="vertical-align:top"><p>1,890</p></td><td style="vertical-align:top"><p>2,025</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,295</p></td><td style="vertical-align:top"><p>2,430</p></td><td style="vertical-align:top"><p>2,565</p></td><td style="vertical-align:top"><p>2,700</p></td></tr><tr><td style="vertical-align:top"><p><strong>23,75</strong></p></td><td style="vertical-align:top"><p>0,713</p></td><td style="vertical-align:top"><p>0,855</p></td><td style="vertical-align:top"><p>0,998</p></td><td style="vertical-align:top"><p>1,140</p></td><td style="vertical-align:top"><p>1,283</p></td><td style="vertical-align:top"><p>1,425</p></td><td style="vertical-align:top"><p>1,568</p></td><td style="vertical-align:top"><p>1,710</p></td><td style="vertical-align:top"><p>1,853</p></td><td style="vertical-align:top"><p>1,995</p></td><td style="vertical-align:top"><p>2,138</p></td><td style="vertical-align:top"><p>2,280</p></td><td style="vertical-align:top"><p>2,423</p></td><td style="vertical-align:top"><p>2,565</p></td><td style="vertical-align:top"><p>2,708</p></td><td style="vertical-align:top"><p>2,850</p></td></tr><tr><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p>0,750</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,500</p></td><td style="vertical-align:top"><p>1,650</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,950</p></td><td style="vertical-align:top"><p>2,100</p></td><td style="vertical-align:top"><p>2,250</p></td><td style="vertical-align:top"><p>2,400</p></td><td style="vertical-align:top"><p>2,550</p></td><td style="vertical-align:top"><p>2,700</p></td><td style="vertical-align:top"><p>2,850</p></td><td style="vertical-align:top"><p>3,000</p></td></tr><tr><td style="vertical-align:top"><p><strong>27,5</strong></p></td><td style="vertical-align:top"><p>0,825</p></td><td style="vertical-align:top"><p>0,990</p></td><td style="vertical-align:top"><p>1,155</p></td><td style="vertical-align:top"><p>1,320</p></td><td style="vertical-align:top"><p>1,485</p></td><td style="vertical-align:top"><p>1,650</p></td><td style="vertical-align:top"><p>1,815</p></td><td style="vertical-align:top"><p>1,980</p></td><td style="vertical-align:top"><p>2,145</p></td><td style="vertical-align:top"><p>2,310</p></td><td style="vertical-align:top"><p>2,475</p></td><td style="vertical-align:top"><p>2,640</p></td><td style="vertical-align:top"><p>2,805</p></td><td style="vertical-align:top"><p>2,970</p></td><td style="vertical-align:top"><p>3,135</p></td><td style="vertical-align:top"><p>3,300</p></td></tr><tr><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,620</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,980</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,340</p></td><td style="vertical-align:top"><p>2,520</p></td><td style="vertical-align:top"><p>2,700</p></td><td style="vertical-align:top"><p>2,880</p></td><td style="vertical-align:top"><p>3,060</p></td><td style="vertical-align:top"><p>3,240</p></td><td style="vertical-align:top"><p>3,420</p></td><td style="vertical-align:top"><p>3,600</p></td></tr><tr><td style="vertical-align:top"><p><strong>32,5</strong></p></td><td style="vertical-align:top"><p>0,975</p></td><td style="vertical-align:top"><p>1,170</p></td><td style="vertical-align:top"><p>1,365</p></td><td style="vertical-align:top"><p>1,560</p></td><td style="vertical-align:top"><p>1,755</p></td><td style="vertical-align:top"><p>1,950</p></td><td style="vertical-align:top"><p>2,145</p></td><td style="vertical-align:top"><p>2,340</p></td><td style="vertical-align:top"><p>2,535</p></td><td style="vertical-align:top"><p>2,730</p></td><td style="vertical-align:top"><p>2,925</p></td><td style="vertical-align:top"><p>3,120</p></td><td style="vertical-align:top"><p>3,315</p></td><td style="vertical-align:top"><p>3,510</p></td><td style="vertical-align:top"><p>3,705</p></td><td style="vertical-align:top"><p>3,900</p></td></tr><tr><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,470</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,890</p></td><td style="vertical-align:top"><p>2,100</p></td><td style="vertical-align:top"><p>2,310</p></td><td style="vertical-align:top"><p>2,520</p></td><td style="vertical-align:top"><p>2,730</p></td><td style="vertical-align:top"><p>2,940</p></td><td style="vertical-align:top"><p>3,150</p></td><td style="vertical-align:top"><p>3,360</p></td><td style="vertical-align:top"><p>3,570</p></td><td style="vertical-align:top"><p>3,780</p></td><td style="vertical-align:top"><p>3,990</p></td><td style="vertical-align:top"><p>4,200</p></td></tr><tr><td style="vertical-align:top"><p><strong>37,5</strong></p></td><td style="vertical-align:top"><p>1,125</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,575</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>2,025</p></td><td style="vertical-align:top"><p>2,250</p></td><td style="vertical-align:top"><p>2,475</p></td><td style="vertical-align:top"><p>2,700</p></td><td style="vertical-align:top"><p>2,925</p></td><td style="vertical-align:top"><p>3,150</p></td><td style="vertical-align:top"><p>3,375</p></td><td style="vertical-align:top"><p>3,600</p></td><td style="vertical-align:top"><p>3,825</p></td><td style="vertical-align:top"><p>4,050</p></td><td style="vertical-align:top"><p>4,275</p></td><td style="vertical-align:top"><p>4,500</p></td></tr><tr><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,920</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,400</p></td><td style="vertical-align:top"><p>2,640</p></td><td style="vertical-align:top"><p>2,880</p></td><td style="vertical-align:top"><p>3,120</p></td><td style="vertical-align:top"><p>3,360</p></td><td style="vertical-align:top"><p>3,600</p></td><td style="vertical-align:top"><p>3,840</p></td><td style="vertical-align:top"><p>4,080</p></td><td style="vertical-align:top"><p>4,320</p></td><td style="vertical-align:top"><p>4,560</p></td><td style="vertical-align:top"><p>4,800</p></td></tr><tr><td style="vertical-align:top"><p><strong>42,5</strong></p></td><td style="vertical-align:top"><p>1,275</p></td><td style="vertical-align:top"><p>1,530</p></td><td style="vertical-align:top"><p>1,785</p></td><td style="vertical-align:top"><p>2,040</p></td><td style="vertical-align:top"><p>2,295</p></td><td style="vertical-align:top"><p>2,550</p></td><td style="vertical-align:top"><p>2,805</p></td><td style="vertical-align:top"><p>3,060</p></td><td style="vertical-align:top"><p>3,315</p></td><td style="vertical-align:top"><p>3,570</p></td><td style="vertical-align:top"><p>3,825</p></td><td style="vertical-align:top"><p>4,080</p></td><td style="vertical-align:top"><p>4,335</p></td><td style="vertical-align:top"><p>4,590</p></td><td style="vertical-align:top"><p>4,845</p></td><td style="vertical-align:top"><p>5,100</p></td></tr></tbody></table><p>&nbsp;</p><p>Table 4 provides guidance for Treprostinil 5 mg/ml for the volume (ml) of Treprostinil to be diluted in 20 ml, 50 ml or 100 ml reservoirs (0.4, 1, or 2 ml/h infusion rates, respectively) for patients of differing body weights corresponding to doses of up to 80 ng/kg/min.</p><p><strong>Table 4</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="17" style="vertical-align:top"><p><strong>Volume (ml) of Treprostinil 5.0 mg/ml to be diluted in cassettes or syringes</strong></p><p><strong>20 ml (0.4 ml/h infusion rate), 50 ml (1 ml/h infusion rate), 100 ml cassette (2 ml/h infusion rate)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Dose (ng/ kg/ min)</strong></p></td><td colspan="16" style="vertical-align:top"><p><strong>Patient Weight (kg)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p><strong>45</strong></p></td><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p><strong>60</strong></p></td><td style="vertical-align:top"><p><strong>65</strong></p></td><td style="vertical-align:top"><p><strong>70</strong></p></td><td style="vertical-align:top"><p><strong>75</strong></p></td><td style="vertical-align:top"><p><strong>80</strong></p></td><td style="vertical-align:top"><p><strong>85</strong></p></td><td style="vertical-align:top"><p><strong>90</strong></p></td><td style="vertical-align:top"><p><strong>95</strong></p></td><td style="vertical-align:top"><p><strong>100</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>10</strong></p></td><td style="vertical-align:top"><p>0,150</p></td><td style="vertical-align:top"><p>0,180</p></td><td style="vertical-align:top"><p>0,210</p></td><td style="vertical-align:top"><p>0,240</p></td><td style="vertical-align:top"><p>0,270</p></td><td style="vertical-align:top"><p>0,300</p></td><td style="vertical-align:top"><p>0,330</p></td><td style="vertical-align:top"><p>0,360</p></td><td style="vertical-align:top"><p>0,390</p></td><td style="vertical-align:top"><p>0,420</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,480</p></td><td style="vertical-align:top"><p>0,510</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,570</p></td><td style="vertical-align:top"><p>0,600</p></td></tr><tr><td style="vertical-align:top"><p><strong>12,5</strong></p></td><td style="vertical-align:top"><p>0,188</p></td><td style="vertical-align:top"><p>0,225</p></td><td style="vertical-align:top"><p>0,263</p></td><td style="vertical-align:top"><p>0,300</p></td><td style="vertical-align:top"><p>0,338</p></td><td style="vertical-align:top"><p>0,375</p></td><td style="vertical-align:top"><p>0,413</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,488</p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,563</p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,638</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,713</p></td><td style="vertical-align:top"><p>0,750</p></td></tr><tr><td style="vertical-align:top"><p><strong>15</strong></p></td><td style="vertical-align:top"><p>0,225</p></td><td style="vertical-align:top"><p>0,270</p></td><td style="vertical-align:top"><p>0,315</p></td><td style="vertical-align:top"><p>0,360</p></td><td style="vertical-align:top"><p>0,405</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,495</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,585</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,765</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,855</p></td><td style="vertical-align:top"><p>0,900</p></td></tr><tr><td style="vertical-align:top"><p><strong>17,5</strong></p></td><td style="vertical-align:top"><p>0,263</p></td><td style="vertical-align:top"><p>0,315</p></td><td style="vertical-align:top"><p>0,368</p></td><td style="vertical-align:top"><p>0,420</p></td><td style="vertical-align:top"><p>0,473</p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,578</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,683</p></td><td style="vertical-align:top"><p>0,735</p></td><td style="vertical-align:top"><p>0,788</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,893</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>0,998</p></td><td style="vertical-align:top"><p>1,050</p></td></tr><tr><td style="vertical-align:top"><p><strong>20</strong></p></td><td style="vertical-align:top"><p>0,300</p></td><td style="vertical-align:top"><p>0,360</p></td><td style="vertical-align:top"><p>0,420</p></td><td style="vertical-align:top"><p>0,480</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,660</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,780</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>0,960</p></td><td style="vertical-align:top"><p>1,020</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,140</p></td><td style="vertical-align:top"><p>1,200</p></td></tr><tr><td style="vertical-align:top"><p><strong>22,5</strong></p></td><td style="vertical-align:top"><p>0,338</p></td><td style="vertical-align:top"><p>0,405</p></td><td style="vertical-align:top"><p>0,473</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,608</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,743</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,878</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>1,013</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,148</p></td><td style="vertical-align:top"><p>1,215</p></td><td style="vertical-align:top"><p>1,283</p></td><td style="vertical-align:top"><p>1,350</p></td></tr><tr><td style="vertical-align:top"><p><strong>25</strong></p></td><td style="vertical-align:top"><p>0,375</p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,750</p></td><td style="vertical-align:top"><p>0,825</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>0,975</p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,125</p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,275</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,425</p></td><td style="vertical-align:top"><p>1,500</p></td></tr><tr><td style="vertical-align:top"><p><strong>27,5</strong></p></td><td style="vertical-align:top"><p>0,413</p></td><td style="vertical-align:top"><p>0,495</p></td><td style="vertical-align:top"><p>0,578</p></td><td style="vertical-align:top"><p>0,660</p></td><td style="vertical-align:top"><p>0,743</p></td><td style="vertical-align:top"><p>0,825</p></td><td style="vertical-align:top"><p>0,908</p></td><td style="vertical-align:top"><p>0,990</p></td><td style="vertical-align:top"><p>1,073</p></td><td style="vertical-align:top"><p>1,155</p></td><td style="vertical-align:top"><p>1,238</p></td><td style="vertical-align:top"><p>1,320</p></td><td style="vertical-align:top"><p>1,403</p></td><td style="vertical-align:top"><p>1,485</p></td><td style="vertical-align:top"><p>1,568</p></td><td style="vertical-align:top"><p>1,650</p></td></tr><tr><td style="vertical-align:top"><p><strong>30</strong></p></td><td style="vertical-align:top"><p>0,450</p></td><td style="vertical-align:top"><p>0,540</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>0,990</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,170</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,530</p></td><td style="vertical-align:top"><p>1,620</p></td><td style="vertical-align:top"><p>1,710</p></td><td style="vertical-align:top"><p>1,800</p></td></tr><tr><td style="vertical-align:top"><p><strong>32,5</strong></p></td><td style="vertical-align:top"><p>0,488</p></td><td style="vertical-align:top"><p>0,585</p></td><td style="vertical-align:top"><p>0,683</p></td><td style="vertical-align:top"><p>0,780</p></td><td style="vertical-align:top"><p>0,878</p></td><td style="vertical-align:top"><p>0,975</p></td><td style="vertical-align:top"><p>1,073</p></td><td style="vertical-align:top"><p>1,170</p></td><td style="vertical-align:top"><p>1,268</p></td><td style="vertical-align:top"><p>1,365</p></td><td style="vertical-align:top"><p>1,463</p></td><td style="vertical-align:top"><p>1,560</p></td><td style="vertical-align:top"><p>1,658</p></td><td style="vertical-align:top"><p>1,755</p></td><td style="vertical-align:top"><p>1,853</p></td><td style="vertical-align:top"><p>1,950</p></td></tr><tr><td style="vertical-align:top"><p><strong>35</strong></p></td><td style="vertical-align:top"><p>0,525</p></td><td style="vertical-align:top"><p>0,630</p></td><td style="vertical-align:top"><p>0,735</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,155</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,365</p></td><td style="vertical-align:top"><p>1,470</p></td><td style="vertical-align:top"><p>1,575</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,785</p></td><td style="vertical-align:top"><p>1,890</p></td><td style="vertical-align:top"><p>1,995</p></td><td style="vertical-align:top"><p>2,100</p></td></tr><tr><td style="vertical-align:top"><p><strong>37,5</strong></p></td><td style="vertical-align:top"><p>0,563</p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,788</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>1,013</p></td><td style="vertical-align:top"><p>1,125</p></td><td style="vertical-align:top"><p>1,238</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,463</p></td><td style="vertical-align:top"><p>1,575</p></td><td style="vertical-align:top"><p>1,688</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,913</p></td><td style="vertical-align:top"><p>2,025</p></td><td style="vertical-align:top"><p>2,138</p></td><td style="vertical-align:top"><p>2,250</p></td></tr><tr><td style="vertical-align:top"><p><strong>40</strong></p></td><td style="vertical-align:top"><p>0,600</p></td><td style="vertical-align:top"><p>0,720</p></td><td style="vertical-align:top"><p>0,840</p></td><td style="vertical-align:top"><p>0,960</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,320</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,560</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,920</p></td><td style="vertical-align:top"><p>2,040</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,280</p></td><td style="vertical-align:top"><p>2,400</p></td></tr><tr><td style="vertical-align:top"><p><strong>42,5</strong></p></td><td style="vertical-align:top"><p>0,638</p></td><td style="vertical-align:top"><p>0,765</p></td><td style="vertical-align:top"><p>0,893</p></td><td style="vertical-align:top"><p>1,020</p></td><td style="vertical-align:top"><p>1,148</p></td><td style="vertical-align:top"><p>1,275</p></td><td style="vertical-align:top"><p>1,403</p></td><td style="vertical-align:top"><p>1,530</p></td><td style="vertical-align:top"><p>1,658</p></td><td style="vertical-align:top"><p>1,785</p></td><td style="vertical-align:top"><p>1,913</p></td><td style="vertical-align:top"><p>2,040</p></td><td style="vertical-align:top"><p>2,168</p></td><td style="vertical-align:top"><p>2,295</p></td><td style="vertical-align:top"><p>2,423</p></td><td style="vertical-align:top"><p>2,550</p></td></tr><tr><td style="vertical-align:top"><p><strong>45</strong></p></td><td style="vertical-align:top"><p>0,675</p></td><td style="vertical-align:top"><p>0,810</p></td><td style="vertical-align:top"><p>0,945</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,215</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,485</p></td><td style="vertical-align:top"><p>1,620</p></td><td style="vertical-align:top"><p>1,755</p></td><td style="vertical-align:top"><p>1,890</p></td><td style="vertical-align:top"><p>2,025</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,295</p></td><td style="vertical-align:top"><p>2,430</p></td><td style="vertical-align:top"><p>2,565</p></td><td style="vertical-align:top"><p>2,700</p></td></tr><tr><td style="vertical-align:top"><p><strong>47,5</strong></p></td><td style="vertical-align:top"><p>0,713</p></td><td style="vertical-align:top"><p>0,855</p></td><td style="vertical-align:top"><p>0,998</p></td><td style="vertical-align:top"><p>1,140</p></td><td style="vertical-align:top"><p>1,283</p></td><td style="vertical-align:top"><p>1,425</p></td><td style="vertical-align:top"><p>1,568</p></td><td style="vertical-align:top"><p>1,710</p></td><td style="vertical-align:top"><p>1,853</p></td><td style="vertical-align:top"><p>1,995</p></td><td style="vertical-align:top"><p>2,138</p></td><td style="vertical-align:top"><p>2,280</p></td><td style="vertical-align:top"><p>2,423</p></td><td style="vertical-align:top"><p>2,565</p></td><td style="vertical-align:top"><p>2,708</p></td><td style="vertical-align:top"><p>2,850</p></td></tr><tr><td style="vertical-align:top"><p><strong>50</strong></p></td><td style="vertical-align:top"><p>0,750</p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,500</p></td><td style="vertical-align:top"><p>1,650</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,950</p></td><td style="vertical-align:top"><p>2,100</p></td><td style="vertical-align:top"><p>2,250</p></td><td style="vertical-align:top"><p>2,400</p></td><td style="vertical-align:top"><p>2,550</p></td><td style="vertical-align:top"><p>2,700</p></td><td style="vertical-align:top"><p>2,850</p></td><td style="vertical-align:top"><p>3,000</p></td></tr><tr><td style="vertical-align:top"><p><strong>55</strong></p></td><td style="vertical-align:top"><p>0,825</p></td><td style="vertical-align:top"><p>0,990</p></td><td style="vertical-align:top"><p>1,155</p></td><td style="vertical-align:top"><p>1,320</p></td><td style="vertical-align:top"><p>1,485</p></td><td style="vertical-align:top"><p>1,650</p></td><td style="vertical-align:top"><p>1,815</p></td><td style="vertical-align:top"><p>1,980</p></td><td style="vertical-align:top"><p>2,145</p></td><td style="vertical-align:top"><p>2,310</p></td><td style="vertical-align:top"><p>2,475</p></td><td style="vertical-align:top"><p>2,640</p></td><td style="vertical-align:top"><p>2,805</p></td><td style="vertical-align:top"><p>2,970</p></td><td style="vertical-align:top"><p>3,135</p></td><td style="vertical-align:top"><p>3,300</p></td></tr><tr><td style="vertical-align:top"><p><strong>60</strong></p></td><td style="vertical-align:top"><p>0,900</p></td><td style="vertical-align:top"><p>1,080</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,620</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>1,980</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,340</p></td><td style="vertical-align:top"><p>2,520</p></td><td style="vertical-align:top"><p>2,700</p></td><td style="vertical-align:top"><p>2,880</p></td><td style="vertical-align:top"><p>3,060</p></td><td style="vertical-align:top"><p>3,240</p></td><td style="vertical-align:top"><p>3,420</p></td><td style="vertical-align:top"><p>3,600</p></td></tr><tr><td style="vertical-align:top"><p><strong>65</strong></p></td><td style="vertical-align:top"><p>0,975</p></td><td style="vertical-align:top"><p>1,170</p></td><td style="vertical-align:top"><p>1,365</p></td><td style="vertical-align:top"><p>1,560</p></td><td style="vertical-align:top"><p>1,755</p></td><td style="vertical-align:top"><p>1,950</p></td><td style="vertical-align:top"><p>2,145</p></td><td style="vertical-align:top"><p>2,340</p></td><td style="vertical-align:top"><p>2,535</p></td><td style="vertical-align:top"><p>2,730</p></td><td style="vertical-align:top"><p>2,925</p></td><td style="vertical-align:top"><p>3,120</p></td><td style="vertical-align:top"><p>3,315</p></td><td style="vertical-align:top"><p>3,510</p></td><td style="vertical-align:top"><p>3,705</p></td><td style="vertical-align:top"><p>3,900</p></td></tr><tr><td style="vertical-align:top"><p><strong>70</strong></p></td><td style="vertical-align:top"><p>1,050</p></td><td style="vertical-align:top"><p>1,260</p></td><td style="vertical-align:top"><p>1,470</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,890</p></td><td style="vertical-align:top"><p>2,100</p></td><td style="vertical-align:top"><p>2,310</p></td><td style="vertical-align:top"><p>2,520</p></td><td style="vertical-align:top"><p>2,730</p></td><td style="vertical-align:top"><p>2,940</p></td><td style="vertical-align:top"><p>3,150</p></td><td style="vertical-align:top"><p>3,360</p></td><td style="vertical-align:top"><p>3,570</p></td><td style="vertical-align:top"><p>3,780</p></td><td style="vertical-align:top"><p>3,990</p></td><td style="vertical-align:top"><p>4,200</p></td></tr><tr><td style="vertical-align:top"><p><strong>75</strong></p></td><td style="vertical-align:top"><p>1,125</p></td><td style="vertical-align:top"><p>1,350</p></td><td style="vertical-align:top"><p>1,575</p></td><td style="vertical-align:top"><p>1,800</p></td><td style="vertical-align:top"><p>2,025</p></td><td style="vertical-align:top"><p>2,250</p></td><td style="vertical-align:top"><p>2,475</p></td><td style="vertical-align:top"><p>2,700</p></td><td style="vertical-align:top"><p>2,925</p></td><td style="vertical-align:top"><p>3,150</p></td><td style="vertical-align:top"><p>3,375</p></td><td style="vertical-align:top"><p>3,600</p></td><td style="vertical-align:top"><p>3,825</p></td><td style="vertical-align:top"><p>4,050</p></td><td style="vertical-align:top"><p>4,275</p></td><td style="vertical-align:top"><p>4,500</p></td></tr><tr><td style="vertical-align:top"><p><strong>80</strong></p></td><td style="vertical-align:top"><p>1,200</p></td><td style="vertical-align:top"><p>1,440</p></td><td style="vertical-align:top"><p>1,680</p></td><td style="vertical-align:top"><p>1,920</p></td><td style="vertical-align:top"><p>2,160</p></td><td style="vertical-align:top"><p>2,400</p></td><td style="vertical-align:top"><p>2,640</p></td><td style="vertical-align:top"><p>2,880</p></td><td style="vertical-align:top"><p>3,120</p></td><td style="vertical-align:top"><p>3,360</p></td><td style="vertical-align:top"><p>3,600</p></td><td style="vertical-align:top"><p>3,840</p></td><td style="vertical-align:top"><p>4,080</p></td><td style="vertical-align:top"><p>4,320</p></td><td style="vertical-align:top"><p>4,560</p></td><td style="vertical-align:top"><p>4,800</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Training for patients receiving continuous intravenous infusion</u></strong></p><p>The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device. A period of personal instruction and supervision should continue until the patient is judged competent to change infusions, alter flow rates / doses as instructed, and be able to deal with common device alarms. Patients must be trained in proper aseptic technique when preparing the treprostinil infusion reservoir and priming the infusion delivery tubing and connection. Written guidance, either from the pump manufacturer or specifically tailored advice by the prescribing physician, must be made available to the patient. This would include the required normal drug delivery actions, advice on how to manage occlusions and other pump alarms, and details of whom to contact in an emergency.</p><p><strong>Minimising the risk of catheter related blood stream infections</strong></p><p>Particular attention must be given to the following to help minimise the risk of catheter related blood stream infections in patients that are receiving Redunix via intravenous infusion (see section 4.4). This advice is in accordance with the current best practice guidelines for the prevention of catheter- related blood stream infections, and includes:</p><p><em>General principles</em></p><p>&bull; use of a cuffed and tunnelled central venous catheter (CVC) with a minimum number of ports.</p><p>&bull; insertion of the CVC using sterile barrier techniques.</p><p>&bull; use of proper hand hygiene and aseptic techniques when the catheter is inserted, replaced, accessed, repaired or when the catheter insertion site is examined and/or dressed.</p><p>&bull; a sterile gauze (replaced every two days) or sterile transparent semi-permeable dressing</p><p>&bull; (replaced at least every seven days) should be used to cover the catheter insertion site.</p><p>&bull; the dressing should be replaced whenever it becomes damp, loosened, or soiled or after examination of the site.</p><p>&bull; topical antibiotic ointments or creams should not be applied as they may promote fungal infections and antimicrobial-resistant bacteria.</p><p><em>Duration of use of diluted Redunix solution</em></p><p>&bull; the maximum duration of use of the diluted product should be no more than 24 hours.</p><p><em>Use of in-line 0.2 micron filter</em></p><p>&bull; a 0.2 micron filter must be placed between the infusion tubing and the catheter hub, and replaced every 24 hours at the time of changing the infusion reservoir.</p><p>Two further recommendations that are potentially important for the prevention of water-borne Gram negative blood stream infections, relate to management of the catheter hub. These include:</p><p><em>Use of a split septum closed hub system</em></p><p>&bull; the use of a closed-hub system (preferably a split septum rather than a mechanical valve device), ensures that the lumen of the catheter is sealed each time the infusion system is disconnected. This prevents the risk of exposure to microbial contamination.</p><p>&bull; the split-septum closed hub device should be replaced every 7 days.</p><p><em>Infusion system luer lock inter-connections</em></p><p>The risk of contamination with water-borne Gram negative organisms is likely to be increased if a luer lock inter-connection is wet at the time of exchanging either the infusion line or the closed hub. Therefore:</p><p>&bull; swimming and submersion of the infusion system at the site of connection with the catheter hub should be discouraged.</p><p>&bull; at the time of replacing the closed-hub device, there should not be any water visible in the luer lock connection threads.</p><p>&bull; the infusion line should only be disconnected from the closed hub device once every 24 hours at the time of replacement.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	pulmonary arterial hypertension related to veno-occlusive disease
•	congestive heart failure due to severe left ventricular dysfunction
•	severe liver impairment (Child-Pugh Class C)
•	active gastrointestinal ulcer, intracranial haemorrhage, injury or other bleeding condition
•	congenital or acquired valvular defects with clinically relevant myocardial dysfunction not related to pulmonary hypertension
•	severe coronary heart disease or unstable angina; myocardial infarction within the last six months; decompensated cardiac failure if not under close medical supervision; severe arrhythmias; cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last three months

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The decision to initiate therapy with Redunix should take into consideration the high probability that a continuous infusion will have to be continued for a prolonged period. Thus the patient&#39;s ability to accept and to be responsible for an indwelling catheter and infusion device should be carefully considered.</p><p>Redunix is a potent pulmonary and systemic vasodilator. In subjects presenting with low systemic arterial pressure, Redunix treatment may increase the risk of systemic hypotension. Treatment is not recommended for patients with systolic arterial pressure of less than 85 mmHg.</p><p>It is recommended to monitor systemic blood pressure and heart rate during any change in dose with instructions to stop the infusion if symptoms of hypotension develop, or a systolic blood pressure of 85 mmHg or lower is detected.</p><p>Abrupt withdrawal or sudden marked reductions in the dose of Redunix may cause a rebound in pulmonary arterial hypertension (see section 4.2).</p><p>If a patient contracts pulmonary oedema while on Redunix, the possibility of an associated pulmonary veno-occlusive disease should be considered. The treatment should be stopped.</p><p>Obese patients (BMI greater than 30 kg/m2) clear Redunix more slowly.</p><p>The benefit of Redunix subcutaneous treatment in patients with more severe pulmonary arterial hypertension (NYHA functional class IV) has not been established.</p><p>The efficacy/safety ratio of treprostinil has not been studied in pulmonary arterial hypertension associated with left-right cardiac shunt, portal hypertension, or HIV infection.</p><p>Patients with hepatic and renal impairment should be dosed cautiously (see Section 4.2).</p><p>As treprostinil and its metabolites are excreted mainly through the urinary route, caution is recommended when treating patients with renal impairment in order to prevent deleterious consequences related to the possible increase of systemic exposure (see Section 4.2).</p><p>Caution is advised in situations where Redunix may increase the risk of bleeding by inhibiting platelet aggregation.</p><p>Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g. gemfibrozil) may increase exposure (both C<sub>max </sub>and AUC) to Redunix. Increased exposure is likely to increase adverse events associated with Redunix administration. Redunix dose reduction should be considered (see section 4.5).</p><p>Co-administration of a CYP2C8 enzyme inducer (e.g. rifampicin) may decrease exposure to Redunix. Decreased exposure is likely to reduce clinical effectiveness. Redunix dose increase should be considered (see section 4.5).</p><p><u>Adverse Events Attributable to the Intravenous Drug Delivery System:</u></p><p>Central venous catheter associated blood stream infections and sepsis have been reported in patients receiving Redunix by intravenous infusion. These risks are attributable to the drug delivery system. A Centers for Disease Control retrospective survey of seven centres in the United States that used intravenous Redunix for the treatment of PAH found an incidence rate for catheter-related bloodstream infections of 1.10 events per 1000 catheter days. Clinicians should be aware of the range of possible Gram-negative and Gram-positive organisms that may infect patients with long-term central venous catheters, therefore, continuous subcutaneous infusion of undiluted Redunix is the preferred mode of administration.</p><p>The clinical team responsible for the therapy must ensure that the patient is fully trained and competent to use the chosen infusion device (see section 4.2).</p><p><u>Excipients</u></p><p>This medicinal product contains 74.8 mg sodium per vial, equivalent to 3.7 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>+ Diuretics, antihypertensive agents, or other vasodilators</strong></p><p>Concomitant administration of treprostinil with diuretics, antihypertensive agents or other vasodilators increases the risk of systemic hypotension.</p><p><strong>+ Platelet aggregation inhibitors, including NSAIDs and anticoagulants</strong></p><p>Treprostinil may inhibit platelet function. Concomitant administration of treprostinil with platelet aggregation inhibitors, including NSAIDs, nitric oxide donors or anticoagulants may increase the risk of bleeding. Surveillance of patients taking anticoagulants should be closely maintained in accordance with conventional medical practice recommendations when monitoring such treatments. The concomitant use of other platelet inhibitors should be avoided in patients taking anticoagulants. Continuous subcutaneous infusion of treprostinil had no effect on pharmacodynamics and pharmacokinetics of a single dose (25 mg) of warfarin. There are no data available on the potential interactions leading to increased risk of bleeding if treprostinil is co-prescribed with nitric oxide donors.</p><p><strong>+ Furosemide</strong></p><p>Treprostinil plasma clearance may be slightly reduced in patients treated with furosemide.</p><p>This interaction is probably due to some common metabolic features shared by both compounds (carboxylate group glucuroconjugation).</p><p><strong>+ Cytochrome P450 (CYP) 2C8 Enzyme Inducers/Inhibitors</strong></p><p>Gemfibrozil - Human pharmacokinetic studies with oral treprostinil diolamine indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil doubles the exposure (both Cmax and AUC) to treprostinil. It has not been determined if the safety and efficacy of treprostinil by the parenteral (subcutaneous or intravenous) route are altered by inhibitors of CYP2C8. If a CYP2C8 inhibitor (e.g. gemfibrozil, trimethoprim and deferasirox) is added to or subtracted from the patient&#39;s medications after the titration period, treprostinil dose adjustment should be considered.</p><p>Rifampicin &ndash; Human pharmacokinetic studies with oral treprostinil diolamine indicated that co-administration of the CYP2C8 enzyme inducer rifampicin decreases exposure to treprostinil (by approximately 20%). It has not been determined if the safety and efficacy of treprostinil by the parenteral (subcutaneous or intravenous) route are altered by rifampicin. If rifampicin is added to or subtracted from the patient&#39;s medications after the titration period, treprostinil dose adjustment should be considered.</p><p>CYP2C8 inducers (e.g. phenytoin, carbamazepine, phenobarbital and St John&#39;s Wort) may reduce the exposure to treprostinil. If a CYP2C8 inducer is added to or subtracted from the patient&#39;s medications after the titration period, treprostinil dose adjustment should be considered.</p><p><strong>+Bosentan</strong></p><p>In a human pharmacokinetic study conducted with bosentan (250 mg/day) and treprostinil diolamine (oral dose 2 mg/day), no pharmacokinetic interactions between treprostinil and bosentan were observed.</p><p><strong>+ Sildenafil</strong></p><p>In a human pharmacokinetic study conducted with sildenafil (60 mg/day) and treprostinil diolamine (oral dose 2 mg/day), no pharmacokinetic interactions between treprostinil and sildenafil were observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>No adequate data on the use of treprostinil in pregnant women are available. Animal studies are insufficient with respect to effects on pregnancy (see section 5.3). The potential risk for humans is unknown. Treprostinil should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the foetus.</p><p><strong>Women of child-bearing potential</strong></p><p>Contraception is recommended during treprostinil treatment.</p><p><strong>Lactation</strong></p><p>It is not known whether treprostinil is excreted in human milk. Breastfeeding women taking treprostinil should be advised to discontinue breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The initiation of treatment or dosage adjustments may be accompanied by undesirable effects such as symptomatic systemic hypotension or dizziness which may impair ability to drive and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions observed in placebo-controlled studies and post-marketing experience with treprostinil are ranked according to frequency using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt; 1/10); uncommon (&ge;1/1,000 to &lt; 1/100); rare (&ge;1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p><u>Tabulated list of adverse reactions</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Vasodilatation, flushing</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bleeding event<sup>&sect;</sup></p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombophlebitis*</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea, nausea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Generalized rashes (macular or papular in</p><p>nature)</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p></td><td style="vertical-align:top"><p>Jaw pain</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia, Arthralgia, Pain in extremity</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Bone pain</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Infusion site pain, infusion site reaction, bleeding or haematoma.</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Oedema</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system</strong>&nbsp;<strong>disorders</strong></p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Central venous catheter-associated blood stream infection, sepsis, bacteremia<strong>**</strong></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Infusion site infection, subcutaneous infusion site abscess formation</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Cellulitis</p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>High output cardiac failure</p></td><td style="vertical-align:top"><p>Not known</p></td></tr></tbody></table><p>* Cases of thrombophlebitis associated with peripheral intravenous infusion have been reported</p><p><strong>**&nbsp;</strong>Life-threatening and fatal cases have been reported</p><p>&sect; See section &laquo;Description of selected adverse events&raquo;</p><p><u>Description of selected adverse events</u></p><p><em>Bleeding events</em></p><p>Bleeding events were common as expected in this patient population with a high proportion of patients treated with anticoagulants. Due to its effects on platelet aggregation, treprostinil may increase the risk of bleeding, as observed by an increased incidence of epistaxis and gastrointestinal (GI) bleeding (including gastrointestinal haemorrhage, rectal haemorrhage, gum haemorrhage and melaena) in controlled clinical trials. There were also reports of haemoptysis, haematemesis and haematuria, but these occurred with the same or lower frequency than in the placebo group.</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u></p><p><strong><u>Saudi Arabia:</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>The National Pharmacovigilance Centre (NPC):</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>SFDA Call Center: 19999 </u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>E-mail: </u>npc.drug@sfda.gov.sa<u> </u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Website: </u>https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong><u>Other GCC States:</u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Please contact the relevant competent authority.</u></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms of overdose with treprostinil are similar to the effects likely to limit dose increases; they include flushing, headache, hypotension, nausea, vomiting, and diarrhoea. Patients experiencing symptoms of overdose should immediately reduce or discontinue their dose of treprostinil depending on the severity of the symptoms until the symptoms of overdose have resolved. Dosing should be recommenced with caution under medical control and patients monitored closely for recurrence of unwanted symptoms.</p><p>No antidote is known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: PLATELET AGGREGATION INHIBITORS, EXCLUDING HEPARIN ATC code: B01A C21</p><p><strong><u>Mechanism of action:</u></strong><strong>&nbsp;</strong>Treprostinil is a prostacyclin analogue.</p><p>It exerts a direct vasodilation effect on the pulmonary and systemic arterial circulation and, inhibits platelet aggregation.</p><p>In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of treprostinil on heart rate in animals varies with the dose. No major effects on cardiac conduction have been observed.</p><p><strong><u>Data on efficacy in adults with pulmonary arterial hypertension:</u></strong></p><p><u>Studies with subcutaneously administered treprostinil</u></p><p>Two phase III randomised, double-blind, placebo-controlled clinical trials have been conducted with treprostinil administered by subcutaneous continuous infusion in subjects with stable pulmonary arterial hypertension. A total of 469 adults were included in the two trials: 270 presented with idiopathic or heritable pulmonary arterial hypertension (treprostinil group = 134 patients; placebo group = 136 patients), 90 patients presented with pulmonary arterial hypertension associated with connective tissue disease (mainly scleroderma) (treprostinil group = 41 patients; placebo group = 49 patients) and 109 patients presented with pulmonary arterial hypertension associated with congenital cardiopathy with left-right shunt (treprostinil = 58 patients; placebo = 51 patients). At baseline, the mean 6-minute walking test distance was 326 metres&nbsp;<u>+</u>&nbsp;5 in the group receiving treprostinil through subcutaneous infusion and 327 metres&nbsp;<u>+</u>&nbsp;6 in the group receiving placebo. The dose of both treatments being compared was progressively increased during the study according to pulmonary arterial hypertension symptoms and clinical tolerance. The mean dose achieved after 12 weeks was 9.3 ng/kg/min in the treprostinil group and 19.1 ng/kg/min in the placebo group. After 12 weeks of treatment, the mean variation in the 6-minute walk test compared to baseline, calculated on the global population from both trials, was -2 metres &plusmn; 6.61 metres in the patients receiving treprostinil and -21.8 metres &plusmn; 6.18 metres in the placebo group. These results reflected a mean treatment effect assessed by the 6-minute walk test of 19.7 metres (p = 0.0064) compared to placebo for the global population from both trials. Mean changes compared to baseline values in haemodynamic parameters (mean pulmonary arterial pressure (PAPm)), right atrial pressure (RAP), pulmonary vascular resistance (PVR), cardiac index (CI) and venous oxygen saturation (SvO<sub>2</sub>) showed treprostinil to be superior to placebo. The improvement in signs and symptoms of pulmonary hypertension (syncope, dizziness, chest pain, fatigue and dyspnoea) was statistically significant (p&lt; 0.0001). In addition the Dyspnoea-Fatigue Rating and Borg Dyspnoea Score were improved in patients treated with treprostinil after 12 weeks (p&lt; 0.0001). Analysis of a combined criterion associating the improvement of exercise capacity (6- minute walk test) of at least 10% compared to baseline after 12 weeks, an improvement by at least one NYHA class compared to baseline after 12 weeks and absence of deterioration in pulmonary hypertension together with lack of death reported before week 12 for the global population of both studies showed the number of subjects responding to treprostinil to be 15.9% (37/233) while 3.4% (8/236) of subjects in the placebo group responded. Sub-group analysis of the global population showed a statistically significant treatment effect of treprostinil compared to placebo on the 6-minute walk test in the sub-population of subjects with idiopathic or heritable pulmonary arterial hypertension (p=0.043) but not in the sub-population of subjects with pulmonary arterial hypertension associated with scleroderma or congenital cardiopathy.</p><p>The effect seen on the primary endpoint (i.e., change in six minute walk distance after 12 weeks treatment) was smaller than that seen in historical controls with bosentan, iloprost and epoprostenol.</p><p>No study directly comparing treprostinil and epoprostenol intravenous infusion has been conducted. No specific study has been conducted in children with PAH.</p><p>There are no data from clinical studies conducted with active comparator in patients with PAH.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In humans, steady-state plasma concentrations are usually achieved within 15 to 18 hours of the initiation of either subcutaneous or intravenous infusion of treprostinil. Steady-state plasma concentrations of treprostinil are dose-proportional at infusion rates of 2.5 up to 125 ng/kg/min.</p><p>Subcutaneous and intravenous administration of treprostinil demonstrated bioequivalence at steady state at a dose of 10 ng/kg/min.</p><p>The mean apparent elimination half-life following subcutaneous administration ranged from 1.32 to 1.42 hours after infusions over 6 hours, 4.61 hours after infusions over 72 hours, and 2.93 hours after infusions lasting at least three weeks. The mean volume of distribution for treprostinil ranged from 1.11 to 1.22 l/kg, and plasma clearance ranged from 586.2 to 646.9 ml/kg/h. Clearance is lower in obese subjects (BMI &gt; 30 kg/m<sup>2</sup>).</p><p>In a study conducted on healthy volunteers using [<sup>14</sup>C] radioactive treprostinil, 78.6% and 13.4% of the subcutaneous radioactive dose were recovered in the urine and faeces respectively over a period of 224 hours. No single major metabolite was observed. Five metabolites were detected in the urine, ranging from 10.2% to 15.5% of the dose administered. These five metabolites accounted for a combined total of 64.4%. Three are products of oxidation of the 3-hydroxyloctyl side chain, one is a glucuroconjugated derivative (treprostinil glucuronide) and one is unidentified. Only 3.7% of the dose was recovered in the urine as unchanged parent drug.</p><p>In a seven-day chronic pharmacokinetic study in 14 healthy volunteers with treprostinil doses ranging from 2.5 to 15 ng/kg/min administered by subcutaneous infusion, steady state plasma treprostinil concentrations reached peak levels twice (at 1 a.m. and 10 a.m. respectively) and trough levels twice (at 7 a.m. and 4 p.m. respectively). The peak concentrations were approximately 20% to 30% higher than the trough concentrations.</p><p>An&nbsp;<em>in vitro&nbsp;</em>study demonstrated no inhibitory potential of treprostinil to human hepatic microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A).</p><p>Moreover, administration of treprostinil had no inducing effect on hepatic microsomal protein, total cytochrome (CYP) P 450 content or on the activities of the isoenzymes CYP1A, CYP2B and CYP3A. Drug interaction studies have been carried out with paracetamol (4 g/day) and warfarin (25 mg/day) in healthy volunteers. These studies did not show a clinically significant effect on the pharmacokinetics of treprostinil. A study conducted with warfarin found no apparent pharmacodynamic nor pharmacokinetic interaction between treprostinil and warfarin.</p><p>The metabolism of treprostinil mainly involves CYP2C8.</p><p><strong><u>Special Populations</u></strong></p><p><u>Hepatic impairment:</u></p><p>In patients with portopulmonary hypertension and mild (n=4) or moderate (n=5) hepatic insufficiency, treprostinil at a subcutaneous dose of 10 ng/kg/min for 150 minutes had an AUC&nbsp;<sub>0-24 h</sub>&nbsp;that was increased 260 % and 510 %, respectively, compared to healthy subjects. Clearance in patients with hepatic insufficiency was reduced by up to 80% compared to healthy adults (see Section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 13 and 26 week studies continuous subcutaneous infusions of treprostinil sodium caused infusion site reactions in rats and dogs (oedema/erythema, masses/swellings, pain/sensitivity to touch). In dogs severe clinical effects (hypoactivity, emesis, loose stool and infusion site oedema) and death (associated with intestinal intussusceptions and rectal prolapse) were observed in animals administered &ge;300 ng/kg/min. Mean steady state plasma treprostinil levels of 7.85 ng/ml were measured in these animals. Plasma levels of this order may be achieved in humans treated with treprostinil infusions at &gt;50 ng/kg/min.</p><p>As a continuously sufficient exposure to treprostinil has not been proven for any dosage tested in the reproductive studies in rats, these studies might be insufficient regarding possible effects on fertility, prenatal and postnatal development.</p><p>No long-term animal studies have been performed to evaluate treprostinil&#39;s carcinogenic potential. In vitro and in vivo mutagenicity studies did not show treprostinil to have any mutagenic or clastogenic effect.</p><p>In summary, preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride USP, Metacresol USP, Sodium citrate dihydrate USP-NF, Sodium hydroxide USP-NF, Hydrochloric acid USP-NF(for pH adjustment), Nitrogen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product should not be mixed with other medicinal products, except for Sterile Water for Injection or 0.9% (w/v) Sodium Chloride Injection (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
After first opening: 30 days
Shelf life during use with continuous subcutaneous administration.
Chemical and physical in-use stability of a single reservoir (syringe) of undiluted Treprostinil administered subcutaneously has been demonstrated for up to 72 hours at 37°C. Other in-use storage times and conditions are the responsibility of the user.
Shelf life during use with continuous intravenous administration.

Chemical, physical and microbiological in-use stability of a single reservoir (syringe) of diluted Treprostinil solution administered by intravenous infusion has been demonstrated for up to 48 hours at 40 °C at concentrations as low as 0.004 mg/ml in polyvinyl chloride, polypropylene and glass. However, to minimise the risk of blood stream infections the maximum duration of use of the diluted Treprostinil should be no more than 24 hours. Other in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C (see section 6.3 for in-use storage times and conditions).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20 mL moulded clear glass vial with 20 mm neck finish, 20 mm Teflon laminated grey coloured rubber stopper and Aluminium Flip off Seal.</p><p>Each carton contains one vial.</p><p>Not all Strengths may be Marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Redunix solution should be used <u>undiluted</u> if administered by continuous subcutaneous infusion (see section 4.2).</p><p>Redunix solution <u>should be diluted</u> with Sterile Water for Injection or 0.9% (w/v) Sodium Chloride Injection, if administered by continuous intravenous infusion (see section 4.2).</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC) 
King Fahad Road –Riyadh Gallery Mall, Gate A1, 3rd floor Sudair pharma office, Building  7639, Riyadh 12262, Saudi Arabia 
Tel: +966-11-920001432 
Fax: +966-11-4668195 
Email: info@sudairpharma.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This leaflet was last revised in 12.2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>